Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online April 8, 2019.
Article Versions
- previous version (October 25, 2018 - 06:38).
- You are viewing the most recent version of this article.
Copyright & Usage
© PDA, Inc. 2019
Author Information
- Jeffrey Weber1,
- James Hauschild2,
- Pieta Ijzerman-Boon3,
- Ren-Yo Forng4,
- Jeff Horsch5,
- Lisa Yan6,
- Aditya Prasad7,
- Robert “Bo” Henry8,
- Marja Claassen3,
- Philip Villari9,
- Shebeer Shereefa10,
- Jane Wyatt11,
- Jay S. Bolden12,
- Jean-Thierry Pycke13 and
- Dawood Dassu14,*
- 1Pfizer, Kalamazoo, MI, USA;
- 2Johnson & Johnson, East Raritan, NJ, USA;
- 3Merck, Sharp & Dohme, The Netherlands;
- 4Amgen, Thousand Oaks, CA, USA;
- 5Bristol-Myers Squibb, New Brunswick, NJ, USA;
- 6Takeda Pharmaceutical Company limited, Los Angeles, CA, USA;
- 7AstraZeneca, Philadelphia, PA, USA;
- 8Catalent Biologics, Bloomington, IN, USA;
- 9Merck Inc., West Point, PA, USA;
- 10Abbvie, North Chicago, IL, USA;
- 11Alexion, Blanchardstown, Dublin, Ireland;
- 12Eli Lilly, Indianapolis, IN, USA;
- 13GSK Vaccines, Belgium; and
- 14BioPhorum, The Gridiron Building, One Pancras Square, London N1C 4AG
- ↵* Corresponding Author: BioPhorum Operations Group, 5 Westbrook Court, Sharrow Vale Road, Sheffield S11 8YZ, UK; e-mail: dawood{at}biophorum.com
Cited By...
Jump to section
- Article
- Abstract
- Introduction to Biofluorescent Particle Counting
- Opportunities and Challenges of Settle Plates and Active Air Sampling
- Role of the Bfpc In Manufacturing
- Potential Implementation Strategy
- Data Collection and Presentation
- Grade A Manufacturing Areas, Restricted Access Barrier System, and Isolators
- Data Sets
- Grade B/C/D Areas
- Regulatory Perception
- Business Benefits
- Conclusions
- Conflicts of Interest Declaration
- Acknowledgements
- References
- Figures & Data
- References
- Info & Metrics
Related Articles
Cited By...
- A Commentary on "Understanding the Non-Equivalency of Bio-Fluorescent Particle Counts versus the Colony Forming Unit"
- Challenges Encountered in the Implementation of Bio-Fluorescent Particle Counting Systems as a Routine Microbial Monitoring Tool
- A Discussion on Bio-Fluorescent Particle Counters: Summary of the Process and Environmental Monitoring Methods Working Group Meeting with the FDA Emerging Technology Team
- Environmental and Personnel Monitoring Programs--A Risk-Based Case Study of Cutibacterium acnes
- Practical Applications of Biofluorescent Particle Counting in Environmental Monitoring Investigations